SCM
BBIO icon

Silvant Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Silvant Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,581
Closed -$43K – 334
2021
Q4 		$43K Sell
2,581
-165
-6% -$6.98K 0.01% 282
2021
Q3 		$129K Hold
2,746
– – 0.02% 210
2021
Q2 		$167K Hold
2,746
– – 0.03% 197
2021
Q1 		$169K Buy
+2,746
New +$180K 0.03% 198

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Silvant Capital Management's BBIO Position: Q1 2022 in Review

Silvant Capital Management sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 2,581 shares — an estimated $43K sold.

Silvant Capital Management first reported a position in BBIO in Q1 2021 and held it in 4 quarters. The position peaked at $169K in Q1 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

  • Silvant Capital Management reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
  • Silvant Capital Management sold 2,581 BridgeBio Pharma shares in Q1 2022, an estimated $43K.
  • Silvant Capital Management first reported a position in BridgeBio Pharma in Q1 2021 and held it in 4 quarters.
  • Silvant Capital Management's BridgeBio Pharma position peaked at $169K in Q1 2021.
  • 178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on Silvant Capital Management's 13F filing for Q1 2022, filed 5 May 2022.